Natco Pharma

NATCO PHARMA NEWS

After Dr Reddy’s, Natco Pharma moves Delhi HC to revoke patent over semaglutide by Novo Nordisk in India

January 07, 2026 10:47 am

The Delhi High Court issued notice to Novo Nordisk seeking its response to Natco Pharma’s suit.

‘From Rs 18 lakh to Rs 48,000 a month, I can finally afford therapy within my salary’: Delhi HC allows Natco to manufacture Roche’s rare disease drug

October 11, 2025 12:59 pm

Natco Pharmaceuticals wins case against international pharmaceutical giant Roche; patients of spinal muscular atrophy heave a sigh of relief.

Natco Pharma receives six observations from USFDA

August 13, 2019 3:41 am

The regulator conducted inspections at the Kothur facility during August 5-9, 2019.

Relief for Natco: US court junks Teva’s patent on Copaxone

June 20, 2015 1:45 am

Generic pharma firms may launch the multiple sclerosis drug.

Natco Pharma wins patent war against Israeli drug giant Teva Pharmaceuticals

November 15, 2013 5:27 am

Hyderabad co may now get permission to launch Copaxone’s generic version in US by 2014

Natco Pharma wins patent case against Teva in US

November 15, 2013 3:34 am

The drug has annual sales worldwide of over $4 billion including $2.2 billion in the US.

Bayer to approach HC against order on Nexavar

March 08, 2013 3:05 am

Bayer holds the patent right for Nexavar in India until 2020 and it will continue to defend its intellectual property rights within the Indian legal system,the spokesperson said.

Pharma Dept proposes negotiating patent drug rates

September 02, 2012 1:02 pm

DoP has reached out to Ministry of Health to negotiate with companies to bring down cost of patented drugs.

Natco Pharma Q1 net profit up 21.66%

August 11, 2012 6:50 pm

The company had posted a net profit of Rs 14.03 crore for the corresponding quarter previous fiscal.

US accuses India of WTO rules violation over Nexavar: Report

July 13, 2012 9:56 pm

US said India of violating norms by allowing Natco to make generic version of cancer drug Nexavar.

Advertisement
Advertisement
Advertisement